Overview

Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO

Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Taiwan Liposome Company